2020HR阳性乳腺癌治疗进展(必威体育精装版推荐).pptxVIP

HR+/HER2- Breast Cancer;HER2+ EBC;TN and HER2+ MBC;LIST;ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106;;Baseline Characteristics (1);Baseline Characteristics (2);Breakdown of Endocrine Response Categories by Arm;Primary Endpoint Resultbr /Endocrine-Sensitive Disease Rate (ESDR) = mPEPI 0 + pCR rate;Ki67 at Baseline vs at Week 4;Conclusion;Letrozole plus ribociclib compared to letrozole plus placebo as neoadjuvant therapy for ER positive early breast cancer (FELINE trial)br /;Background;Background – Response assessment on neoadjuvant endocrine therapy;br /Trial Design: Femara + LEE011 (ribociclib) as neoadjuvant endocrine therapy in breast cancer br /;Treatment and data completion;Primary Endpoint: PEPI 0 at Surgery;Results: Clinical and Radiologic Responses (%);br /Results: Ki-67 change between baseline and D14C1br /;Adverse Events of Interest;Conclusions;LIST;MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients;Slide 2;;Slide 5;MINDACT successfully met its primary endpointbr /SUMMARY OF CONCLUSIONS OF PRIMARY ANALYSIS (5y median FU);UPDATED ANALYSIS AT 8.7 YEARS MEDIAN FOLLOW-UPbr /br /RESULTS;Update of PRIMARY ENDPOINT with more mature data at 5 years (90% of pts with at least 5 years FU);At 8.7y median FU, DMFS in 4 risk groupsbr /br /Excellent prognosis and low rate of events in all groups except Clinical High/Genomic High;SECONDARY ENDPOINTbr /DMFS C-High/G-Low risk (ITT population) CT vs no CT;SECONDARY ENDPOINTbr /C-High/G-Low risk (ITT population) CT vs no CTbr /ITT analysis;DMFS in C-High / G-Low risk patients with br /luminal cancers (HR+/HER2-) stratified by agebr /ITT population;DMFS in C-High / G-Low risk patients with br /luminal cancers (HR+/HER2-) stratified by agebr /ITT population;